Bio Medica Laboratories IPO
Market Sentiment
IPO Details
IPO Reservation
Market Lot Size
Financial Analysis
| Metric | 2023 | 2024 | 2025 | Nov 2025 |
|---|---|---|---|---|
| Revenue | 16.25 | 15.34 | 38.33 | 28.63 |
| Expense | 15.80 | 11.69 | 25.18 | 16.95 |
| Profit (PAT) | 0.33 | 2.50 | 9.79 | 8.66 |
| Total Assets | 17.57 | 19.53 | 39.12 | 65.17 |
| Company | EPS | P/E |
|---|---|---|
| Zenotech Laboratories Limited | 0.92 | - |
| Shukra Pharmaceuticals Limited | 0.22 | 47.57 |
Promoters: Mr. Mukesh Mehta and Mr. Pradeep Mehta
| Shareholding | No. of Shares | Holding % |
|---|---|---|
| Promoter Holding Pre Issue | 91,80,001 | 99.99% |
Strengths & Risks
- Strong institutional (QIB) demand — 15.9x.
- Revenue grew 150% in the latest reported year.
- Solid profit margin — 25.5%.
- Strong return on equity — 100%.
- Mostly fresh capital — proceeds fund the company's growth, not an exit.
- Elevated leverage — debt/equity of 1.02.
Auto-generated from live GMP, subscription, valuation and financial data. Informational only — not investment advice. Always read the RHP before applying.
Company Information
Bio Medica Laboratories is one of the leading manufacturers of parenteral medicines (injectable products) in India. The firm has been involved in developing a wide range of parenteral medicines targeting both human and animal needs. They manufacture generic medicines in the form of Liquid injections and dry powder injections, which come in various forms of packaging like ampoules and vials.
| Purpose | Amount (Cr) |
|---|---|
| Repayment of Loan | 7.25 |
| Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises | 24.81 |
| General Corporate Purpose | - |
Resources & Documents
Bio Medica Laboratories Ltd., Plot No. 11B-11C, Sector-E, Sanwer Road, Industrial Area, Industrial Estate (Indore),, Indore, Madhya Pradesh, 452015
Bio Medica Laboratories has set a price band of Rs 132–Rs 139 per share for an issue size of Rs 52 crore. The stock listed with a 20.00% discount versus its issue price on May 29, 2026.
Bio Medica Laboratories is one of the leading manufacturers of parenteral medicines (injectable products) in India. The firm has been involved in developing a wide range of parenteral medicines targeting both human and animal needs.
The issue is promoted by Mr. Mukesh Mehta and Mr. Pradeep Mehta with Narnolia Financial Services Ltd. acting as lead manager. Net proceeds will primarily be used towards Repayment of Loan (Rs 7 crore) and Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises (Rs 25 crore).
Grey market is quoting a discount of Rs -6 (-4.3% over issue price), down Rs 10 from the previous session. Final subscription data records overall subscription at 2.31x, retail at 2.92x, QIB at 15.94x, NII at 1.41x.
On fundamentals, the company is posting revenue growth of 149.9%, a profit margin of 25.5%, return on equity of 99.6% in its most recent reported period. Listed peers in this segment include Shukra Pharmaceuticals Limited (P/E 47.57x) — useful reference points when evaluating the issue's pricing relative to where the broader sector is trading.
Our data-driven engine currently flags this issue as an Avoid view — key indicators are weak enough that the risk-reward looks unfavourable for now. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Bio Medica Laboratories IPO GMP — What It Means
The latest grey market premium for Bio Medica Laboratories IPO is ₹-6 (-4.3%). GMP is an unofficial, dealer-quoted figure that hints at expected listing-day demand — it is not a guaranteed listing price. For Bio Medica Laboratories it should be read alongside the subscription numbers and the company's fundamentals, since grey-market premiums can swing sharply during the bidding window.
See the full Bio Medica Laboratories GMP history and trend, or learn how grey market premium works and how reliable it is.
Related IPO
No comments yet. Be the first to share your opinion!